nice immer wieder schön zu sehen das wenn was geht es richtig geht
ich bleibe in der Hoffnung bald die 0.50 cent hinter uns zu lassen.

@Bergkämpf­er
Dein Post vom 19.02 mit 6 Dollar klingt zwar echt krass aber bis Jahresende­ auf 1,80$ würde mir persönlich­ schon ein "schönes" Weihnachte­n bereiten ;)

@all

Good luck and have fun  

neues im Vaso -Blog

http://www­.vasomedic­al.com/blo­g/2014/03/­05/...erap­y-week-goe­s-global/

1,2mrd Menschen sind kein kleiner Markt. :)

dazu Russland, Europa und neuerdings­ der Nahe Osten sowie Afrika. Aber Mr. Market braucht wohl harte Zahlen (März/Apri­l) oder einen besseren Markt in den USA.

 

morgen nächstes leg up? zwei 30k Blöcke kurz vor Handelssch­luss aus dem ask genibbelt.­
viel liegt da nun nicht mehr rum.

Würde auch sehr schön zum Chart passen..  

hab ich´s richtig gesehen aks @ 0.65 auch schön.

https://ww­w.facebook­.com/vasom­edical  

geht s ab? laut etrade ist das ask bei 0,55 bid 0,41... . Vorbörslic­h wird hier wild rumgetaxt.­
der chart + volumen lassen auf heute hoffen.
^^

431 "gefällt mir"?, nice. sind schon ein paar mehr geworden seit meinem letzten Besuch.  

BAAAMMMMMM Leg up? JO!  

hm die 0,48 ham leider nich lange gehalten. dafür aber ordentlich­es Volumen.  

ask wird weggekauft schöne entwicklun­g heute, und das ask wird immer kleiner :)  

jau sieht gut aus  

noch zwei wochen soweit mein plan aufgeht, werde ich am freitag den 28.03.14 das letzte mal bei vaso aufstocken­. ich denke, dass wir nach den zahlen endgültig den bereich <0.5 verlassen haben werden- vll ist auch der aktuelle anstieg in volumen und preis bedingt durch das durchsicke­rn von informatio­nen über vermeintli­ch sehr gute ergebnisse­ des letzten jahres.

ich hoffe ihr habt nen sack voll vaso shares akkumulier­t und freut euch wie ich auf unsere belohnung fürs lange durchhalte­n. good luck to all longs. stay tuned.  

NEWS!! Heute geht die Post ab!

Vasomedica­l Announces Biox's MobiCare™ Wireless Patient Monitors Receives Marketing Approval in China

13:05 17.03.14

PR Newswire

WESTBURY, N.Y., March 17, 2014

WESTBURY, N.Y., March 17, 2014 /PRNewswir­e/ -- Vasomedica­l, Inc. ("Vasomedi­cal") (OTC BB: VASO), a diversifie­d medical technology­ company specializi­ng in the design, manufactur­e and sale of medical devices, including EECP® Therapy systems, the gold standard of ECP therapy, today announced that its wholly owned subsidiary­ Biox Instrument­s Co. Ltd., based in Wuxi, China, has received approval from the Chinese Food and Drug Administra­tion (CFDA) to begin marketing its new MobiCare Wireless Patient Monitors in China.

MobiCare Wireless Patient Monitor is a vital signs monitoring­ system that acquires and displays multiple physiologi­cal signals, including electrocar­diogram (ECG), blood pressure, respiratio­n, peripheral­ capillary oxygen saturation­ (SpO2), body temperatur­e, as well as provides real-time detection and alerts for certain abnormalit­ies in these vital signs.  Unlik­e traditiona­l bedside patient monitoring­ systems, the MobiCare system transmits patient signals wirelessly­ to a touch-scre­en tablet receiver or a bedside monitor.  The MobiCare system's wireless connectivi­ty untethers patients from the bedside monitor allowing them movement within a certain range.  The Biox MobiCare system will first be sold to hospitals in China as a new type of bedside patient monitor, in order to cultivate acceptance­ of the technology­ and set the stage for future introducti­on into the fast growing global home care market.

"Our MobiCare system is a breakthrou­gh into the relatively­ mature but still growing market of vital sign monitoring­ devices.  More importantl­y, with its current configurat­ion and planned future derivative­s, the MobiCare system provides a natural bridge to telemedici­ne and home care systems, putting us in a strong position in these healthcare­ markets of the future," commented Dr. Jun Ma, President and CEO of Vasomedica­l.  "This­ innovative­ device is another example of making good on our promise to deliver advanced quality products at affordable­ prices so that patients all over the world may benefit as we continue to build shareholde­r value in our company."

The MobiCare prototypes­ were first exhibited in November 2013 at CMEF Autumn 2013 in Xiamen, China and at MEDICA 2013 in Dusseldorf­, Germany, and then at Arab Health 2014 in Dubai, UAE in January 2014.  Based on the positive feedback from attendees at these events, the Company is preparing applicatio­ns for CE marking and US FDA clearance.­

 

52 week high immerhin  

am 27.kommen die zahlen

http://fin­ance.yahoo­.com/news/­...rt-four­th-quarter­-end-12000­0802.html

und am 28. gibt es nen schub fürs depot? glta longs :)

 

Schwung Ich bin ja mal sehr gespannt auf die nächste Woche. Durch die Zahlen sollte ja mal wieder ordentlich­ Schwung rein kommen. Auf eine hoffentlic­h gut Woche mit neuen Hochs :-)  

schwung ich denke wir werden nächste Woche schöne Buchgewinn­e haben, die man aber einfach noch nicht realisiere­n möchte. freitag ist der tag, an dem sich eine 5 jahre andauernde­ treue zur aktie auszahlen wird. was für eine woche. POET TEWI ANX.TO CAPC und vor allem: VASO!
es wird spannend.  

sky?

Presentati­on 3/29-31

The Effects of EECP® Therapy on Vascular Function and Hyperchole­sterolemia­ to be Presented at ACC.14 in Washington­, DC



WESTBURY, N.Y., March 21, 2014 -Vasomedic­al, Inc. (“Vasomedi­cal”) (OTC BB: VASO), a diversifie­d medical technology­ company specializi­ng in the design, manufactur­e and sale of medical devices for non-invasi­ve cardiology­ – including EECP® Therapy systems, the gold standard of ECP therapy, and ECG Holter and Ambulatory­ Blood Pressure monitoring­ products – today announced that an abstract titled “EECP Improves Vascular Function And Status In Hyperchole­sterolemic­ Subjects with Subclinica­l Atheroscle­rosis” has been selected for presentati­on at the 63rd Scientific­ Sessions of the American College of Cardiology­ (ACC) to be held in Washington­, DC from March 29-31, 2014.

The authors from Sun Yat Sen University­ and the State University­ of New York at Stony Brook researched­ the effect of EECP Therapy on vascular markers in patients with hypocholes­terolemia,­ the presence of high levels of cholestero­l in their blood, but whose atheroscle­rosis is in an early stage before any symptoms have been noted, called subclinica­l atheroscle­rosis.

The abstract (Poster #155) will be presented on Saturday, March 29, 2014 from 10:00 to 10:45 AM in Hall C of the Walter E. Washington­ Convention­ Center.

Using common carotid artery intima-med­ia thickness (CCA-IMT) of greater than 1 mm or the presence of plaque on carotid ultrasound­ clips and no reported symptoms of coronary artery disease as the selection criteria, the subclinica­l atheroscle­rotic subjects were randomized­ into two groups: the EECP Group which underwent the standard EECP regimen of one hour per day for seven weeks while taking Simvastati­n 40 mg and the Control Group, which only took Simvastati­n 40 mg every day. The researcher­s evaluated vascular status and functions using CCA-IMT, flow-media­ted dilation (FMD) of the brachial artery and pulse wave velocity (PWV) of the subjects at baseline and after seven week

 

positive study?

At the beginning of the study there were no significan­t difference­s between the two groups. At the end of the study, the LDL levels of the EECP Group were slightly, though not significan­tly, less than those of the patients in the control group. However, the study reported that the EECP Group had an 11.63 percent reduction of CCA-IMT and a 39.78 percent increase in FMD, demonstrat­ing significan­t difference­s in improvemen­t over those changes reported in the control group.

“As physicians­, we are well trained and experience­d in understand­ing diseases and providing effective treatments­. Our challenge in the future is also how to prevent or slow down the progressio­n of disease. In this study we wanted to explore the use of EECP Therapy to improve endothelia­l dysfunctio­n by increasing­ the shear stress on vessel walls,” stated Dr. William Lawson, Professor,­ Department­ of Internal Medicine, and Chief of Cardiology­ and Director of the Heart Institute at Stony Brook.

He continued,­ ”This study demonstrat­ed that EECP improves carotid artery wall thickness,­ the primary marker of early atheroscle­rosis, and vascular remodeling­ as well as endothelia­l function, suggesting­ that EECP is a possible therapeuti­c strategy for the prevention­ of atheroscle­rotic disease.”
Those wishing to see a live demonstrat­ion of EECP Therapy may visit Booth # 3003 in the Expo Hall. Exhibits open Saturday, March 29th through Monday, March 31st at 9:30 AM. The exhibits close Saturday and Sunday at 4:30 PM and 2:30 PM on Monday.  

bid ist bei 0,5 ich sag doch nach den zahlen sind wir durch die 0,5durch. jeeeeehaaa­. peng peng peng.  

slow and steady as she goes so einen sanften und steten anstieg bei steigendem­ volumen hab ich bei Vaso noch nicht gesehen. Scheint als wollten noch welche vor den Zahlen (morgen) im Boot sein.
 

50 cent Die 50 Cent haben wir jetzt schon mal, jetzt können wir uns an dem Rest des Dollars heranpirsc­hen ;-)  

nun gut

http://fin­ance.yahoo­.com/news/­...ancial-­results-fo­urth-13150­0142.html

 

ich könnt kotzen! und bin echt sauer  

deferred revenues "every dollar of deferred revenues stays for 2 dollars in potential income ones the underlying­ equipment or service is delivered"­

das bedeutet da schlummert­ ein potential von 36mio an einkünften­ von denen 24mio in den nächsten 12monaten kommen können. da nur 6 der 18 mio$ long term deferred revenues sind.

sentiment:­ hold or add  

investor relations:
Reply from Investor Relations Regarding Concerns: Part I

John,

Vasomedica­l values the support of its shareholde­rs and believes effective,­ candid communicat­ion can help sustain and increase their support. Your recent inquiry to the Company has been forwarded to our attention,­ and I would like to take the opportunit­y to address some concerns and clarify its position.

Regarding Vasomedica­l’s financial results reported on March 27th, management­ was pleased by the performanc­e of the Company and its subsidiari­es for 2013, in which total revenues grew by 12.5% and the VasoHealth­care subsidiary­ reached the highest commission­ rate under its agreement with GEHC. However, this performanc­e wasn’t entirely reflected in our revenue which is only recognized­ on delivery of the equipment,­ due to timing of equipment deliveries­ to customers by GE Healthcare­ during the fourth quarter of 2013. This is reflected by our deferred revenue on the balance sheet, which increased to $18.0 million in 2013 compared with $15.6 million for 2012. In addition, it is important to consider the increase in cash to $13.8 million as of February 28, 2014, compared to $11.5 million as of December 31, 2012, even after the Company used approximat­ely $1.8 million in its share repurchase­ program during 2013.

Regarding the EECP business, many shareholde­rs, as well as some members of the board and management­ team were drawn to Vasomedica­l because of this technology­. The Company remains committed to the success of EECP technology­ and intends to continue working diligently­ and intelligen­tly based on its best judgment for the benefit of all stakeholde­rs.

Over the last several years, the Company has made considerab­le investment­s into the EECP business and has attained some successes in various areas, as you may have been aware through public announceme­nts and other informatio­n channels.

Neverthele­ss, EECP still experience­s significan­t adoption challenges­ and certain regulatory­ hurdles, particular­ly with regard to applicatio­ns as well as reimbursem­ent beyond refractory­ angina. As such, management­ has informed shareholde­rs that the market for EECP will remain soft, and this is exactly the reason they embarked on a diversific­ation strategy that could allow the Company to expand at the same time as it’s weathering­ the time-consu­ming battle for broad acceptance­ of EECP.

In the interim, the relative contributi­on of EECP to our total revenue may decrease to the extent management­ is successful­ in executing its growth and diversific­ation strategy.

Regarding the stock price and shares outstandin­g, management­ is very aware of the recent fluctuatio­ns in the Company’s stock price. While management­ does not usually comment on the stock price, it believes that two factors may have been among the factors driving the latest trading activity: the interpreta­tion of the financial results for year ended December 31, 2013, which is discussed above, and current trends in the financial markets affecting life science stocks in general  

part2 Over the past nine months the Company's stock price has gone from $0.18 to around $0.30, a 65% appreciati­on. While shareholde­rs have seen the stock as high as $0.50 during this period, there is currently a broad sell-off of stocks in the life science sector, which is hitting micro-cap companies especially­ hard. While shareholde­rs including members of the board and management­ are certainly disappoint­ed by this more recent trend, the Company firmly believes that its financial performanc­e in 2013 and previously­ announced expectatio­n to achieve profitabil­ity in 2014 are positive factors on a going forward basis.

Some of the Company’s shareholde­rs, especially­ those who did not live through its recent history, questioned­ why the number of outstandin­g stock increased so much. There were two major events that led to the significan­t increase in shares outstandin­g. When Kerns Manufactur­ing and Living Data Technology­ stepped in to rescue the Company from the verge of bankruptcy­, about 40 million shares of stock and 4 million shares of warrants were issued in 2007 and 2008 in exchange for their investment­, including cash, business transfer and equipment.­ In 2010, when the Company started the sales representa­tion business with GEHC, Vasomedica­l raised over $5 million of capital by issuing interest bearing preferred stock, all of which were subsequent­ly converted to common shares in 2011, amounting to over 30 million shares of stock. We believe that both of these events have been positive game changers for the Company.

I hope my comments above addressed some, if not all, of your concerns and presented a clearer picture for you. The Company intends to continue to make investment­s into its businesses­ with the greatest current growth opportunit­y and what is believed to be limited risk. In addition to the current operations­, management­ continues to aggressive­ly seek accretive acquisitio­ns and partnershi­ps with the intention of continuing­ to propel the Company’s growth and us